Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Placebo-controlled, Double-blind, Multicenter, Seamless Adaptive Phase II-III Clinical Trial to Select the Dose and Evaluate Safety and Efficacy of MAD0004J08 Monoclonal Antibody in Adult Patients With Recently Diagnosed Asymptomatic to Moderately Severe COVID-19

NCT04952805 is registered in ClinicalTrials.gov with Toscana Life Sciences Sviluppo s.r.l. as lead sponsor.

NCT NCT04952805
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04952805 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Placebo-controlled, Double-blind, Multicenter, Seamless Adaptive Phase II-III Clinical Trial to Select the Dose and Evaluate Safety and Efficacy of MAD0004J08 Monoclonal Antibody in Adult Patients With Recently Diagnosed Asymptomatic to Moderately Severe COVID-19
Lead sponsor
Toscana Life Sciences Sviluppo s.r.l.
Phase
Phase 2/3
Overall status
Unknown status
Start date
June 6, 2021
Completion date
August 31, 2022
Enrollment
800 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

covid19